Domenico Motola (Nicola Montanaro)

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 13

Top Topics

Coronavirus Disease

Epidermal Growth Factor Receptor

Top Venues

European journal of clinical pharmacology

Journal of clinical medicine

British journal of clinical pharmacology

Fundamental & clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Victoria Nikitina, Greta Santi Laurini, Domenico Motola, Domenico Motola
Safety profile of paediatric COVID-19 vaccines: An analysis of the US Vaccine Adverse Event Reporting System. Acta paediatrica (Oslo, Norway : 1992) (2023)
Greta Santi Laurini, Domenico Motola, Domenico Motola
Safety of COVID-19 vaccines in pregnancy: a VAERS based analysis. European journal of clinical pharmacology (2023)
Victoria Nikitina, Greta Santi Laurini, Domenico Motola, Domenico Motola
Comparative Safety Profiles of Oncology Biosimilars vs. Originators in Europe: An Analysis of the EudraVigilance Database. Cancers 15 (14) (2023)
Domenico Motola, Greta Santi Laurini, Giulia Bonaldo, Domenico Motola
Level of therapeutic innovation from the registration studies of the new drugs for the prophylaxis of migraine. Journal of clinical pharmacy and therapeutics (2022)
Greta Santi Laurini, Domenico Motola, Domenico Motola
Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data. Journal of clinical medicine 12 (1) (2022)
Greta Santi Laurini, Domenico Motola, Domenico Motola
Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data. Journal of clinical medicine 12 (1) (2022)
Greta Santi Laurini, Domenico Motola, Domenico Motola
Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data. Journal of clinical medicine 12 (1) (2022)
Domenico Motola, Giulia Bonaldo, Domenico Motola
Safety profile of hydroxychloroquine used off-label for the treatment of patients with COVID-19: A descriptive study based on EudraVigilance data. Fundamental & clinical pharmacology 36 (6) (2022)
Domenico Motola, Giulia Bonaldo, Domenico Motola
Removal of the EMA orphan designation upon request of the sponsor: cui prodest? European journal of clinical pharmacology 77 (7) (2021)
Giulia Bonaldo, Domenico Motola, Alberto Vaccheri, Domenico Motola
Human papilloma virus vaccination in males: A pharmacovigilance study on the Vaccine Adverse Event Reporting System. British journal of clinical pharmacology 87 (4) (2020)
Domenico Motola, Domenico Motola
On criteria to evaluate the therapeutic innovation of drugs. British journal of clinical pharmacology 87 (5) (2020)
Domenico Motola, Giulia Bonaldo, Stefania Proni, Giacomo Chiabrando, Domenico Motola
Non-commercial trials on medicines submitted to the Ethics Committee of the University Hospital of Bologna (Italy) along 8 years of activity: time to update rules and recommendations. European journal of clinical pharmacology 75 (10) (2019)
Domenico Motola, Mauro Melis, Stefania Proni, Giacomo Chiabrando, Domenico Motola
Six-year activity on approval of compassionate use of medicines by the Ethics Committee of the University Hospital of Bologna (Italy): time to update rules and recommendations. European journal of clinical pharmacology 73 (4) (2016)